Emily Evans, MD, MBE, EMD Serono, Rockland, MD, discusses the future of multiple sclerosis (MS) treatments. Currently, many effective strategies are available for relapsing-remitting MS; however, progressive MS, characterized by unrelenting neurodegeneration, causes cumulative disability and is refractory to current treatments. Therefore, the next step in the MS space is to develop treatments that can target the total disability accumulation and not just the relapses. Bruton’s Tyrosine Kinase inhibitors (BTKIs), a new class of experimental therapy being intensely evaluated in MS, carry great therapeutic potential across the MS spectrum, including progression independent of relapses. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.